

ABSTRACT – NESHIMA MEDICAL

○ Investment Rational

Neshima is developing novel respiratory treatments, utilizing liquid-foam (LiFT™) for improved penetration of therapeutics into sick lung regions through the trachea. LiFT™ platform can deliver small and large molecules, biologics, large particles, cell therapy, and more. The platform performance was validated on small and large animals. Neshima's team is led by Dr Yan Ostrovski (CEO); and Dr Nissim Darvish (Chairman).

○ Business Strategy

Our target with the first treatment (antibiotics for severe microbial pneumonia) is to sell devices to 1000 US ICUs. The devices will be used with our proprietary drug capsules, projected to generate \$1B+ annually in revenues. Future developments will include treatments for other severe lung diseases with large markets like IPF and COPD. The technology is covered by patent applications.

○ Core Technology

Compared to competing technologies (e.g. Nebulizers), LiFT™ (foam) delivers drugs homogeneously throughout the lungs, including peripheral and obstructed (diseased) lung regions, while dissolving the obstructing mucus plugs. Moreover, the foam can deliver large drug doses into alveoli within seconds (x100 compared to nebulizer; over 1ml/s), and can carry much larger particles (x10 in diameter, 50micron).

○ Product Profile/Pipeline

Neshima is developing a pulmonary drug delivery platform and proprietary treatments. For a shorter time to market, we first focus on delivery of FDA approved drugs (The first product is antibiotics). We are also seeking partnerships with pharma companies, to deliver their drugs with our device. The serviceable obtainable market (SOM) in the USA for our technology is over \$56B.

○ What's Next?

We are currently working on upgrading our device to clinical grade. In parallel, we are preparing for our next preclinical trials (IND enabling). Clinical trials are planned in 2024. We are submitting the Israel Innovation authority R&D grant (Female Entrepreneurship track), with several angel investors. We are looking for strategic partners and more angel investors.